| Business Summary | | Avitar,
Inc.,
through
its
wholly
owned
subsidiary
Avitar
Technologies,
Inc.,
develops,
manufactures,
markets
and
sells
diagnostic
test
products
and
proprietary
hydrophilic
polyurethane
foam
disposables
fabricated
for
medical,
diagnostics,
dental
and
consumer
use.
During
fiscal
2000,
the
Company
continued
the
development
and
marketing
of
point-of-care
oral
fluid
drugs
of
abuse
tests,
which
use
the
Company's
foam
as
the
means
for
collecting
the
oral
fluid
sample.
The
Company's
wholly
owned
subsidiary,
United
States
Drug
Testing
Laboratories,
Inc.,
operates
a
certified
laboratory
and
provides
specialized
drug
testing
services
primarily
utilizing
hair
as
the
sample. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AVR
develops,
manufactures,
markets
and
sells
diagnostic
test
products
and
proprietary
hydrophilic
polyurethane
foam
disposables
fabricated
for
medical,
diagnostics,
dental
and
consumer
use.
For
the
nine
months
ended
6/30/01,
revenues
rose
46%
to
$4.3
million.
Net
loss
applicable
to
Common
and
before
acct.
change
rose
19%
to
$5.9
million.
Results
reflect
higher
sales
of
ORALscreen(TM)
and
BJR,
offset
by
higher
marketing
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Peter Phildius, 70 Chairman
and CEO | $171K | Douglas Scott, 54 Pres,
COO | 162K | Jay Leatherman, Jr., 56 CFO
and Sec. | 108K | Douglas Lewis, 51 VP
and Pres of USDTL | 126K | Carl Good, III, Ph.D., 57 VP
of R&D | 118K | Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|